Program
LY03017
A development code.
Its studies are mostly in Hallucinations · Alzheimer Disease, led by Luye Pharma Group.
Furthest: phase 1, since Apr 24, 20243 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Luye Pharma Group | 32 open or running | phase 1since Apr 24, 2024 | Apr 24, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2024First study: phase 1 study in HallucinationsFirst studyNCT06388551 · 60 enrolled · China
- Jan 20, 2025Phase 1 study in Alzheimer's Disease PsychosisNCT06793995 · 26 planned · China
- May 12, 2025Phase 1 study in HallucinationsNCT06980207 · 40 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06980207Hallucinations · China | 1 | Not yet recruiting | Oct 2025 | 40 |
| NCT06793995Alzheimer's Disease Psychosis · China | 1 | Not yet recruiting | Oct 31, 2025 | 26 |
| NCT06388551Hallucinations · China | 1 | UNKNOWN | Mar 30, 2025 | 60 |
How it is read
Names in the registry
- “LY03017”, 4 entries
Codes read as this program: LY03017.
Conditions, from the studies’ own filings
- Hallucinations, 2 studies
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.